Building upon these findings, we conducted this longitudinal investigation using an extensive global medical records database to explore the associations between GLP-1 RAs and mortality, adverse cardiovascular and kidney-related events in a substantial cohort of individuals with type 2 diabetes concomitant with AKD
181 However, Pegaptanib was withdrawn from the market owing to its poor efficacy and competition from anti-VEGF antibody drugs, such as Lucentis
The physiological changes induced by GIP and GLP-1 receptor activationincluding alterations in gastric emptying, fluid balance, and metabolic parameterscould potentially contribute to sensations of lightheadedness in some individuals, particularly through mechanisms like dehydration or blood pressure changes
For a 200 lb person, Retatrutide would produce approximately 48 lbs of weight loss on average, compared to 42 lbs with Tirzepatide
It is often associated with circulating pro-inflammatory cytokines and immune cells
Teng, M